CN104039358A - 氮清除药物的治疗性监测方法 - Google Patents

氮清除药物的治疗性监测方法 Download PDF

Info

Publication number
CN104039358A
CN104039358A CN201280048373.5A CN201280048373A CN104039358A CN 104039358 A CN104039358 A CN 104039358A CN 201280048373 A CN201280048373 A CN 201280048373A CN 104039358 A CN104039358 A CN 104039358A
Authority
CN
China
Prior art keywords
ammonia
nitrogen
blood ammonia
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280048373.5A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁斯·沙施米德
马苏德·默克塔拉你
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizon Therapeutics LLC
Original Assignee
Horizon Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104039358(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics LLC filed Critical Horizon Therapeutics LLC
Priority to CN201710239760.1A priority Critical patent/CN107271696A/zh
Publication of CN104039358A publication Critical patent/CN104039358A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • G01N31/221—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators for investigating pH value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium
    • Y10T436/175383—Ammonia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
CN201280048373.5A 2011-09-30 2012-03-09 氮清除药物的治疗性监测方法 Pending CN104039358A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710239760.1A CN107271696A (zh) 2011-09-30 2012-03-09 氮清除药物的治疗性监测方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161542100P 2011-09-30 2011-09-30
US61/542,100 2011-09-30
US201161564668P 2011-11-29 2011-11-29
US61/564,668 2011-11-29
PCT/US2012/028620 WO2013048558A2 (en) 2011-09-30 2012-03-09 Methods of therapeutic monitoring of nitrogen scavenging drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710239760.1A Division CN107271696A (zh) 2011-09-30 2012-03-09 氮清除药物的治疗性监测方法

Publications (1)

Publication Number Publication Date
CN104039358A true CN104039358A (zh) 2014-09-10

Family

ID=47892277

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280048373.5A Pending CN104039358A (zh) 2011-09-30 2012-03-09 氮清除药物的治疗性监测方法
CN201710239760.1A Pending CN107271696A (zh) 2011-09-30 2012-03-09 氮清除药物的治疗性监测方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710239760.1A Pending CN107271696A (zh) 2011-09-30 2012-03-09 氮清除药物的治疗性监测方法

Country Status (25)

Country Link
US (21) US8404215B1 (enExample)
EP (2) EP2760479B1 (enExample)
JP (2) JP6073898B2 (enExample)
KR (2) KR102019000B1 (enExample)
CN (2) CN104039358A (enExample)
AU (2) AU2012316750B2 (enExample)
BR (1) BR112014007357B1 (enExample)
CA (1) CA2850391A1 (enExample)
CL (1) CL2014000783A1 (enExample)
CY (1) CY1119028T1 (enExample)
DK (1) DK2760479T3 (enExample)
ES (1) ES2629859T3 (enExample)
HR (1) HRP20171063T1 (enExample)
HU (1) HUE035220T2 (enExample)
IL (2) IL231732A (enExample)
LT (1) LT2760479T (enExample)
MX (2) MX366197B (enExample)
PL (1) PL2760479T3 (enExample)
PT (1) PT2760479T (enExample)
RS (1) RS56196B1 (enExample)
SG (1) SG11201400781TA (enExample)
SI (1) SI2760479T1 (enExample)
SM (1) SMT201700321T1 (enExample)
WO (1) WO2013048558A2 (enExample)
ZA (1) ZA201401851B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2760479T3 (pl) 2011-09-30 2017-09-29 Horizon Therapeutics, Llc Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu
CN111991383A (zh) * 2012-04-20 2020-11-27 伊梅尔迪卡制药公司 苯乙酸前药的治疗性监测方法
LT2922576T (lt) * 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai
US20150094278A1 (en) * 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy
PT2986325T (pt) * 2013-10-14 2019-10-09 Immedica Pharma Ab Métodos para tratar distúrbios do ciclo da ureia
EP3782610A1 (en) 2013-11-14 2021-02-24 Ultragenyx Pharmaceutical Inc. Solid compositions of triglycerides and uses tehreof
ES2861594T3 (es) 2014-04-30 2021-10-06 Univ Johns Hopkins Composiciones de dendrímeros y su uso en el tratamiento de enfermedades del ojo
WO2015187641A1 (en) * 2014-06-04 2015-12-10 Horizon Therapeutics, Inc. Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels
AU2015301575B2 (en) 2014-08-13 2018-05-10 The Johns Hopkins University Selective dendrimer delivery to brain tumors
JP7088473B2 (ja) 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
WO2017147193A1 (en) * 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
JP6752748B2 (ja) 2017-03-30 2020-09-09 住友重機械工業株式会社 減速装置
JP7454945B2 (ja) * 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
MX2020002057A (es) * 2017-08-22 2020-07-13 Regeneron Pharma Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
WO2022011061A1 (en) * 2020-07-07 2022-01-13 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
US20100008859A1 (en) * 2008-04-29 2010-01-14 Scharschmidt Bruce Methods of treatment using ammonia-scavenging drugs

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1004595A (en) 1911-05-25 1911-10-03 Sargents Sons Corp C G Carrier for washing-bowls.
US1018300A (en) 1911-06-12 1912-02-20 John Davidson Condensing steam-engine.
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
CA2212047C (en) 1995-02-07 2010-11-16 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
DE19805854C1 (de) 1998-02-13 1999-05-12 Claas Usines France Schalteinrichtung für Schneidmesser
US6219567B1 (en) * 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
IT1317073B1 (it) 2000-12-12 2003-05-26 Mini Ricerca Scient Tecnolog Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico.
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US6825384B1 (en) 2004-01-29 2004-11-30 The Nutrasweet Company Bromine free TEMPO based catalyst system for oxidation of primary and secondary alcohols using NaOCl as an oxidant
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
WO2009145323A1 (ja) 2008-05-30 2009-12-03 日産化学工業株式会社 多環式化合物を用いるアルコールの酸化方法
ES2593378T3 (es) 2008-08-29 2016-12-09 Horizon Therapeutics, Llc Métodos de tratamiento usando fármacos de secuestro de ammonia
WO2010025303A1 (en) 2008-08-29 2010-03-04 Hyperion Therapeutics Dosing and monitoring patients on nitrogen-scavenging drugs
EP2456304B1 (en) 2009-07-24 2015-08-19 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
EP2594550B1 (en) 2010-07-16 2016-10-12 Tohoku University Method for oxidizing alcohols
US20130224277A1 (en) 2010-08-31 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
PL2760479T3 (pl) 2011-09-30 2017-09-29 Horizon Therapeutics, Llc Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu
EP2607366A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate esters
CN111991383A (zh) 2012-04-20 2020-11-27 伊梅尔迪卡制药公司 苯乙酸前药的治疗性监测方法
LT2922576T (lt) 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai
CN103304402B (zh) 2013-05-24 2015-04-22 苏州诚和医药化学有限公司 一种制备4-苯-1-丁酸的方法
US20150094278A1 (en) 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy
PT2986325T (pt) 2013-10-14 2019-10-09 Immedica Pharma Ab Métodos para tratar distúrbios do ciclo da ureia
WO2015063659A1 (en) 2013-10-30 2015-05-07 Lupin Limited Process for the preparation of glycerol phenylbutyrate
WO2015187641A1 (en) 2014-06-04 2015-12-10 Horizon Therapeutics, Inc. Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels
WO2017147193A1 (en) 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
US20100008859A1 (en) * 2008-04-29 2010-01-14 Scharschmidt Bruce Methods of treatment using ammonia-scavenging drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GREGORY M. ENNS ET AL.: "Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *

Also Published As

Publication number Publication date
US20210000784A1 (en) 2021-01-07
MX2014003854A (es) 2014-10-17
US9326966B2 (en) 2016-05-03
ZA201401851B (en) 2018-05-30
US9962358B2 (en) 2018-05-08
US10617665B2 (en) 2020-04-14
US9095559B2 (en) 2015-08-04
US10045959B1 (en) 2018-08-14
RS56196B1 (sr) 2017-11-30
US20160199334A1 (en) 2016-07-14
JP6073898B2 (ja) 2017-02-01
EP2760479B1 (en) 2017-05-03
US9999608B2 (en) 2018-06-19
JP2014532179A (ja) 2014-12-04
KR20140094517A (ko) 2014-07-30
US20180055807A1 (en) 2018-03-01
US20180263949A1 (en) 2018-09-20
BR112014007357B1 (pt) 2022-12-06
SG11201400781TA (en) 2014-04-28
SMT201700321T1 (it) 2017-09-07
US20160081969A1 (en) 2016-03-24
US20130210914A1 (en) 2013-08-15
AU2012316750B2 (en) 2017-08-31
US20180021291A1 (en) 2018-01-25
EP3263102A1 (en) 2018-01-03
JP2017067791A (ja) 2017-04-06
US20130085179A1 (en) 2013-04-04
HRP20171063T1 (hr) 2017-10-06
US10183006B2 (en) 2019-01-22
PT2760479T (pt) 2017-07-21
CN107271696A (zh) 2017-10-20
DK2760479T3 (en) 2017-07-17
US9962359B2 (en) 2018-05-08
IL231732A0 (en) 2014-05-28
ES2629859T3 (es) 2017-08-16
BR112014007357A2 (pt) 2017-04-04
MX2019006900A (es) 2019-09-04
US10183004B2 (en) 2019-01-22
KR102019000B1 (ko) 2019-09-05
WO2013048558A2 (en) 2013-04-04
IL254134A0 (en) 2017-10-31
CL2014000783A1 (es) 2015-01-16
CA2850391A1 (en) 2013-04-04
LT2760479T (lt) 2017-07-10
AU2017251691A1 (en) 2017-11-09
US20160199333A1 (en) 2016-07-14
US10183005B2 (en) 2019-01-22
US20190125713A1 (en) 2019-05-02
MX366197B (es) 2019-06-25
US20160202240A1 (en) 2016-07-14
US20180221325A1 (en) 2018-08-09
US20150335605A1 (en) 2015-11-26
US20180235920A1 (en) 2018-08-23
SI2760479T1 (sl) 2017-07-31
US20180021293A1 (en) 2018-01-25
KR20180085823A (ko) 2018-07-27
JP6425746B2 (ja) 2018-11-21
US20180015064A1 (en) 2018-01-18
US8404215B1 (en) 2013-03-26
WO2013048558A3 (en) 2014-04-03
US20180221324A1 (en) 2018-08-09
US10045958B1 (en) 2018-08-14
US20160199332A1 (en) 2016-07-14
IL231732A (en) 2017-09-28
EP2760479A4 (en) 2015-08-26
PL2760479T3 (pl) 2017-09-29
AU2012316750A1 (en) 2014-03-27
US9254278B2 (en) 2016-02-09
US20180221326A1 (en) 2018-08-09
US20180263948A1 (en) 2018-09-20
CY1119028T1 (el) 2018-01-10
EP2760479A2 (en) 2014-08-06
US10183002B2 (en) 2019-01-22
US20180221327A1 (en) 2018-08-09
US10183003B2 (en) 2019-01-22
HUE035220T2 (hu) 2018-05-02

Similar Documents

Publication Publication Date Title
US10617665B2 (en) Methods of therapeutic monitoring of nitrogen scavenging drugs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140910

RJ01 Rejection of invention patent application after publication